FrancophonIA/ELRC3.0 huggingface dataset:
English: Lipid parameters should be assessed approximately 12 weeks following initiation of Olumiant therapy and thereafter patients should be managed according to international clinical guidelines for hyperlipidaemia.
Croatian: Lipidne parametre treba odrediti približno 12 tjedana nakon početka liječenja lijekom Olumiant, nakon čega bolesnike treba liječiti u skladu s međunarodnim kliničkim smjernicama za hiperlipidemiju.
English: As of 01 July 2019, 114 VTEs have been reported in 102 cases from post-marketing reports.
Croatian: Do 1. srpnja 2019. godine prijavljeno je 114 događaja VTE-a u
English: Physicians should advise women of child bearing potential to use contraception during treatment and for a week after its ending.
Croatian: Liječnici trebaju savjetovati ženama reproduktivne dobi da koriste kontracepciju tijekom liječenja i još tjedan dana po njegovu završetku.
English: Olumiant has no or negligible influence on the ability to drive and use machines.
Croatian: Olumiant ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Combination with biologic DMARDs or other Janus kinase (JAK) inhibitors is not recommended, as a risk of additive immunosuppression cannot be excluded.
Croatian: Ne preporučuje se primjena u kombinaciji s biološkim DMARD-ovima ili drugim inhibitorima Janus kinaze (JAK) jer se ne može isključiti rizik od aditivne imunosupresije.
English: The JAK/STAT pathway has been shown to be involved in cell adhesion and cell polarity which can affect early embryonic development.
Croatian: Pokazalo se da signalni put JAK/STAT sudjeluje u staničnoj adheziji i staničnoj polarnosti, što može utjecati na rani razvoj embrija.
English: The recommended dose is 4 mg once a day.
Croatian: Preporučena doza je 4 mg jedanput na dan.
English: Clinical Trial Summary Study name (Duration)
Croatian: Naziv ispitivanja (trajanje)
English: RA-BUILD (24 weeks)
Croatian: RA-BUILD (24 tjedna)
English: Potential for baricitinib to affect the pharmacokinetics of other medicinal products
Croatian: Potencijal baricitiniba da djeluje na farmakokinetiku drugih lijekova
English: Abbreviations: ADA = adalimumab; MTX = methotrexate; OLU = Olumiant; PBO = Placebo a Placebo data at week 52 derived using linear extrapolation b No progression defined as mTSS change ≤ 0.
Croatian: Kratice: ADA = adalimumab; MTX = metotreksat; OLU = Olumiant; PBO = Placebo a Podaci za placebo u 52. tjednu dobiveni su linearnom ekstrapolacijom b Izostanak progresije definira se kao promjena mTSS rezultata za ≤ 0
English: Body weight, sex, race, and ethnicity did not have a clinically relevant effect on the PK of baricitinib.
Croatian: Tjelesna težina, spol, rasa i etničko porijeklo nisu imali klinički značajnog učinka na farmakokinetiku baricitiniba.
English: If you take more Olumiant than you should
Croatian: Ako uzmete više lijeka Olumiant nego što ste trebali
English: If HBV DNA is detected, a liver specialist should be consulted to determine if treatment interruption is warranted.
Croatian: Ako se utvrdi prisutnost HBV DNK, treba se savjetovati sa specijalistom za jetrene bolesti kako bi se utvrdilo treba li prekinuti liječenje.
English: If an infection develops, the patient should be monitored carefully and Olumiant therapy should be temporarily interrupted if the patient is not responding to standard therapy.
Croatian: Ako se razvije infekcija, bolesnika treba pažljivo nadzirati, a liječenje lijekom Olumiant privremeno prekinuti ako bolesnik ne odgovara na standardnu terapiju.
English: Olumiant 2 mg and 4 mg are available in blister packs of 14, 28, 35, 56, 84 and 98 tablets in calendar blisters and 28 x 1 and 84 x 1 tablets in perforated unit dose blisters.
Croatian: Olumiant 2 mg i 4 mg tablete dostupne su u pakiranjima od 14, 28, 35, 56, 84 i 98 tableta u kalendarskim blisterima i pakiranjima od 28 x 1 i 84 x 1 tablete u perforiranim blisterima djeljivima na pojedinačne doze.
English: The risk of lymphocytosis is increased in elderly patients with rheumatoid arthritis.
Croatian: Rizik od limfocitoze povećan je u starijih bolesnika s reumatoidnim artritisom.
English: In addition, for both study RA-BEACON and RA-BUILD, onset of efficacy was faster and the effect size was generally larger for the 4 mg dose groups compared to 2 mg.
Croatian: Osim toga, i u ispitivanju RA-BEACON i u ispitivanju RA-BUILD nastup djelotvornosti bio je brži, a učinak općenito veći u skupini koja je primala dozu od 4 mg u usporedbi s onom koja je primala dozu od 2 mg.
English: What Olumiant contains - The active substance is baricitinib.
Croatian: Što Olumiant sadrži - Djelatna tvar je baricitinib.
English: Olumiant is not recommended for use in patients with creatinine clearance < 30 mL/min (see section 5.2).
Croatian: Primjena lijeka Olumiant ne preporučuje se u bolesnika s klirensom kreatinina < 30 ml/min (vidjeti dio 5.2).
English: On the basis of the scientific conclusions for baricitinib the CHMP is of the opinion that the benefitrisk balance of the medicinal product(s) containing baricitinib is unchanged subject to the proposed changes to the product information
Croatian: Na temelju znanstvenih zaključaka za baricitinib, CHMP smatra da je omjer koristi i rizika lijeka(ova) koji sadrži(e) baricitinib nepromijenjen, uz predložene izmjene informacija o lijeku.
English: The tablets contain a recessed area on each side.
Croatian: Tablete na obje strane imaju udubljenje.
English: Six placebo-controlled studies were integrated (997 patients on 4 mg once daily and 1070 patients on placebo) to evaluate the safety of Olumiant in comparison to placebo for up to 16 weeks after treatment initiation.
Croatian: Objedinjeni su podaci iz šest placebom kontroliranih ispitivanja (997 bolesnika liječenih dozom od 4 mg jedanput na dan i 1070 bolesnika koji su primali placebo) radi ocjenjivanja sigurnosti lijeka Olumiant u usporedbi s placebom tijekom razdoblja do 16 tjedana nakon početka liječenja.
English: Patients with hepatitis B surface antibody and hepatitis B core antibody, without hepatitis B surface antigen, were also allowed to participate; such patients should be monitored for expression of hepatitis B virus (HBV) DNA.
Croatian: Sudjelovati su mogli i bolesnici koji su imali protutijela na površinski i jezgreni antigen virusa hepatitisa B, ali ne i površinski antigen virusa hepatitisa B; takve bolesnike treba nadzirati zbog moguće ekspresije DNK virusa hepatitisa B
English: This could be a sign of a herpes zoster infection.
Croatian: To bi mogao biti znak infekcije koja se zove herpes zoster
English: This may be due to inhibition of creatinine secretion by baricitinib in the renal tubules.
Croatian: To bi mogla biti posljedica inhibicije lučenja kreatinina uslijed djelovanja baricitiniba u bubrežnim tubulima.
English: No adverse foetal effects were observed at exposures 2 times the human exposure based on AUC.
Croatian: Nisu primijećeni štetni učinci na plod pri razinama izloženosti koje su bile 2 puta veće od one u ljudi na temelju AUC-a.
English: Taking into account the PRAC Assessment Report on the PSUR(s) for baricitinib, the scientific conclusions of CHMP are as follows:
Croatian: (PSUR) za baricitinib, znanstveni zaključci CHMP-a su sljedeći:
English: • That Olumiant increases the potential risk of infections.
Croatian: • Upozorenje da Olumiant povećava mogući rizik od infekcija.
English: Very common side effects (may affect more than 1 in 10 people): - throat and nose infections - high levels of blood fat (cholesterol) shown by blood test
Croatian: Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba): - infekcije grla i nosa - visoke razine masnoća (kolesterola) u krvi, vidljive u nalazima krvnih pretraga
English: Patients, who were positive for hepatitis C antibody but negative for hepatitis C virus RNA, were allowed to participate.
Croatian: Bolesnicima koji su bili pozitivni na protutijela na virus hepatitisa C, ali negativni na RNK virusa hepatitisa C bilo je dopušteno sudjelovati u ispitivanjima.
English: • Fever, wounds, feeling more tired than usual, or dental problems.
Croatian: • vrućica, rane, pojačan umor ili problemi sa zubima
English: • That the Patient Alert Card should be carried by the patient at any time and to share it with other healthcare professionals involved in their treatment.
Croatian: • Napomenu da bolesnik uvijek sa sobom mora nositi karticu s upozorenjima za bolesnika i pokazati je svim drugim zdravstvenim radnicima koji sudjeluju u njegovu liječenju.
English: Cmax and AUC at steady state are 1.4- and 2.0-fold higher, respectively, in subjects with rheumatoid arthritis compared to healthy subjects.
Croatian: Utvrđeno je da su Cmax i AUC u stanju dinamičke ravnoteže za 1,4 odnosno 2,0 puta viši u ispitanika s reumatoidnim artritisom nego u zdravih ispitanika.
English: Treatment should be started by a doctor experienced in the diagnosis and treatment of rheumatoid arthritis.
Croatian: Liječenje mora započeti liječnik s iskustvom u dijagnosticiranju i liječenju reumatoidnog artritisa.
English: You should swallow your tablet with a drink of water.
Croatian: Tabletu progutajte cijelu, s vodom.
English: Concomitant use of the OAT3 inhibitors ibuprofen and diclofenac may lead to increased exposure of baricitinib, however their inhibition potential of OAT3 is less compared to probenecid and thus a clinically relevant interaction is not expected.
Croatian: Iako istodobna primjena inhibitora prijenosnika OAT3 ibuprofena i diklofenaka može povećati izloženost baricitinibu, potencijal tih lijekova da inhibiraju OAT3 manji je nego onaj probenecida i stoga se ne očekuje klinički značajna interakcija.
English: In all 4 studies, a significantly higher proportion of patients treated with Olumiant 4 mg compared to placebo or MTX achieved low disease activity or remission (DAS28-ESR or DAS28-hsCRP ≤ 3.2 and DAS28-ESR or DAS28-hsCRP < 2.6) at Weeks 12 and 24.
Croatian: U sva je 4 ispitivanja značajno veći udio bolesnika liječenih lijekom Olumiant u dozi od 4 mg nego onih koji su primali placebo ili metotreksat postigao nisku aktivnost bolesti ili remisiju (DAS28-ESR ili DAS28-hsCRP ≤ 3,2 i DAS28-ESR ili DAS28-hsCRP < 2,6) u 12. i 24. tjednu.
English: For Olumiant, the most common serious infections were herpes zoster, and cellulitis.
Croatian: Najčešće ozbiljne infekcije uz Olumiant bile su herpes zoster i celulitis.
English: Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function.
Croatian: Janus kinaze su enzimi koji prenose unutarstanične signale s receptora na površini stanica za niz citokina i faktora rasta uključenih u hematopoezu, upalni proces i imunosnu funkciju.
English: For the total population, pneumococcal vaccination resulted in a satisfactory IgG immune response in 68.0 % (95 % CI: 58.4 %, 76.2 %) of the patients.
Croatian: Cijepljenje protiv pneumokoka dovelo je do zadovoljavajućeg imunološkog odgovora IgG-a u 68,0% (95% CI: 58,4%; 76,2%) bolesnika iz cjelokupne populacije.
English: Keep this information with you and share it with other healthcare professionals involved in your medical care or treatment.
Croatian: Molimo, nosite ovu karticu sa sobom i pokažite je svim zdravstvenim radnicima koji sudjeluju u vašem liječenju.
English: The risk of malignancies including lymphoma is increased in patients with rheumatoid arthritis.
Croatian: Rizik od zloćudnih bolesti, uključujući limfom, povećan je u bolesnika s reumatoidnim artritisom.
English: The clinical data are insufficient to assess the potential incidence of malignancies following exposure to baricitinib.
Croatian: Nema dovoljno kliničkih podataka da bi se ocijenila potencijalna incidencija zloćudnih bolesti nakon izlaganja baricitinibu.
English: Abbreviations: ADA = adalimumab; MTX = methotrexate; OLU = Olumiant; PBO = Placebo * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 vs. placebo (vs. MTX for study RA-BEGIN) † p ≤ 0.05; †† p ≤ 0.01; ††† p ≤ 0.001 vs. adalimumab
Croatian: Kratice: ADA = adalimumab; MTX = metotreksat; OLU = Olumiant; PBO = Placebo * p ≤ 0,05; ** p ≤ 0,01; *** p ≤ 0,001 u odnosu na placebo (u odnosu na metotreksat u ispitivanju RA-BEGIN) † p ≤ 0,05; †† p ≤ 0,01; ††† p ≤ 0,001 u odnosu na adalimumab
English: Animal studies indicate that baricitinib may have an adverse effect on bone development in utero at higher dosages.
Croatian: Ispitivanja na životinjama ukazuju da bi baricitinib pri višim dozama mogao štetno djelovati na razvoj kostiju in utero.
English: Week 24 0.14 0.06 0.03 0.29 0.12** Week 52 0.21 0.25 0.06 0.58 0.21*** 0.19** Proportion of patients with no radiographic progressionb:
Croatian: 24. tjedan 0,14 0,06 0,03 0,29 0,12** 52. tjedan 0,21 0,25 0,06 0,58 0,21*** 0,19** Udio bolesnika bez radiografske progresijeb:
English: Polyvinylchloride/polyethylene/polychlorotrifluoroethylene - aluminium blisters in cartons of 14, 28, 35, 56, 84 or 98 film-coated tablets.
Croatian: Blisteri od polivinilklorida/polietilena/poliklorotrifluoroetilena i aluminija u kutijama koje sadrže 14, 28, 35, 56, 84 ili 98 filmom obloženih tableta.
English: • Use effective contraception while taking Olumiant (and for 1 week after, if you stop treatment).
Croatian: • Koristite učinkovitu kontracepciju tijekom liječenja lijekom Olumiant (i još tjedan dana nakon njegova završetka)
English: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 vs. placebo (vs. MTX for study RA-BEGIN)
Croatian: * p ≤ 0,05; ** p ≤ 0,01; *** p ≤ 0,001 u odnosu na placebo (u odnosu na metotreksat u ispitivanju RA-BEGIN)
English: Following oral administration, baricitinib is rapidly absorbed with a median tmax of approximately 1 hour (range 0.5 - 3.0 h) and an absolute bioavailability of approximately 79 % (CV = 3.94 %).
Croatian: Baricitinib se nakon peroralne primjene brzo apsorbira, uz medijan tmax od približno 1 sata (raspon: 0,5 - 3,0 h) i apsolutnu bioraspoloživost od približno 79% (coefficient of variation, CV = 3,94%).
English: Single doses up to 40 mg and multiple doses of up to 20 mg daily for 10 days have been administered in clinical trials without dose-limiting toxicity.
Croatian: U kliničkim su se ispitivanjima primjenjivale jednokratne doze do 40 mg i višestruke doze do 20 mg na dan tijekom 10 dana bez znakova toksičnosti koja bi ograničavala dozu.
English: Use of baricitinib with potent immunosuppressive medicinal products such as azathioprine, tacrolimus, or ciclosporin was limited in clinical studies of baricitinib, and a risk of additive immunosuppression cannot be excluded (see section 4.4).
Croatian: Primjena baricitiniba sa snažnim imunosupresivima kao što su azatioprin, takrolimus ili ciklosporin bila je ograničena u kliničkim ispitivanjima baricitiniba i ne može se isključiti rizik od aditivne imunosupresije (vidjeti dio 4.4).
English: The most commonly reported adverse drug reactions (ADRs) occurring in ≥ 2 % of patients treated with Olumiant monotherapy or in combination with conventional synthetic DMARDs were increased LDL cholesterol (33.6 %), upper respiratory tract infections (14.7 %) and nausea (2.8 %).
Croatian: Najčešće prijavljene nuspojave lijeka koje su se javile u ≥ 2% bolesnika liječenih lijekom Olumiant u monoterapiji ili u kombinaciji s konvencionalnim sintetskim DMARD-ovima bile su povišene vrijednosti LDL-kolesterola (33,6%), infekcije gornjih dišnih putova (14,7%) i mučnina (2,8%).
English: The influence of baricitinib on the humoral response to non-live vaccines was evaluated in 106 RA patients under stable treatment with baricitinib 2 or 4 mg, receiving inactivated pneumococcal or tetanus vaccination.
Croatian: Utjecaj baricitiniba na humoralni odgovor na neživa cjepiva ocjenjivao se u 106 bolesnika s reumatoidnim artritisom koji su primali stabilnu terapiju baricitinibom u dozi od 2 ili 4 mg i koji su primili inaktivirano cjepivo protiv pneumokoka ili tetanusa.
English: Uncommon side effects (may affect up to 1 in 100 people): - low number of white bloods cells (neutrophils), shown by blood test - increase in an enzyme called creatine kinase, shown by blood test - high levels of blood fat (triglycerides), shown by blood test - acne - weight gain - swelling of the face - urticaria - blood clots in the blood vessels of the lungs - blood clot in the veins of the legs or pelvis, called a deep vein thrombosis (DVT)
Croatian: Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba): - nizak broj bijelih krvnih stanica (neutrofila), vidljiv u nalazima krvnih pretraga - porast razine enzima koji se zove kreatin fosfokinaza, vidljiv u nalazima krvnih pretraga - visoke razine masnoća (triglicerida) u krvi, vidljive u nalazima krvnih pretraga - akne - porast tjelesne težine - oticanje lica - urtikarija - krvni ugrušci u krvnim žilama pluća - krvni ugrušci u venama nogu ili zdjelice, što se naziva dubokom venskom trombozom (DVT)
English: Potential for other medicinal products to affect the pharmacokinetics of baricitinib
Croatian: Potencijal drugih lijekova da utječu na farmakokinetiku baricitiniba
English: In placebo-controlled trials in which MTX was not required, 501 subjects randomized to baricitinib 2 mg or 4 mg received MTX as background therapy, and 303 received conventional DMARDs other than MTX (approximately half with MTX and half without).
Croatian: U placebom kontroliranim ispitivanjima u kojima metotreksat nije bio obavezan, 501 ispitanik randomiziran za primanje baricitiniba u dozi od 2 mg ili 4 mg primao je metotreksat kao osnovnu terapiju, dok je njih 303 primalo druge konvencionalne DMARD-ove (približno polovica njih zajedno s metotreksatom, a polovica bez metotreksata).
English: Olumiant is used to treat adults with moderate to severe rheumatoid arthritis, an inflammatory disease of the joints, if previous therapy did not work well enough or was not tolerated.
Croatian: Olumiant se koristi za liječenje odraslih osoba s umjerenim do teškim reumatoidnim artritisom upalnom bolešću zglobova - ako prethodna terapija nije djelovala dovoljno dobro ili ako je bolesnik nije podnosio.
English: Following oral administration of baricitinib, a dose-proportional increase in systemic exposure was observed in the therapeutic dose range.
Croatian: Nakon peroralne primjene baricitiniba primijećeno je povećanje sistemske izloženosti proporcionalno dozi unutar terapijskog raspona doza.
English: The efficacy and safety of Olumiant once daily was assessed in 4 Phase III randomised, double-blind, multicentre studies in patients with moderate to severe active rheumatoid arthritis diagnosed according to the ACR/EULAR 2010 criteria (see Table 3).
Croatian: 4 randomizirana, dvostruko slijepa, multicentrična ispitivanja faze III provedena u bolesnika s umjerenim do teškim oblikom aktivnog reumatoidnog artritisa, dijagnosticiranim prema ACR/EULAR kriterijima iz 2010. godine (vidjeti Tablicu 3).
English: Skin and subcutaneous tissue disorders
Croatian: Poremećaji kože i potkožnog tkiva osip akne
English: In a clinical pharmacology study, baricitinib was excreted predominately as the unchanged active substance in urine (69 %) and faeces (15 %) and only 4 minor oxidative metabolites were identified (3 in urine; 1 in faeces) constituting approximately 5 % and 1 % of the dose, respectively.
Croatian: U kliničkom farmakološkom ispitivanju baricitinib se prvenstveno izlučivao kao neizmijenjena djelatna tvar kroz mokraću (69%) i feces (15%), a pronađena su svega 4 manje značajna oksidativna metabolita (3 u mokraći, 1 u fecesu), koja su činila približno
English: In vitro, baricitinib is a cytochrome P450 enzyme (CYP)3A4 substrate although less than 10 % of the dose is metabolised via oxidation.
Croatian: In vitro je baricitinib supstrat enzima 3A4 citokroma P450 (CYP3A4), iako se manje od 10% doze metabolizira oksidacijom.
English: Degeneration of the sternal growth plate was observed in some dogs, at low incidence and also in control animals, but with a dose-effect relationship regarding severity.
Croatian: U nekih je pasa primijećena degeneracija ploče rasta sternuma; incidencija je bila niska, a pojava je zabilježena i u kontrolnih životinja, dok je težinu određivao odnos između doze i učinka.
English: Keep this medicine out of the sight and reach of children.
Croatian: Kako čuvati Olumiant Lijek čuvajte izvan pogleda i dohvata djece.
English: Tablet cores
Croatian: Jezgre tablete
English: Treatment should be initiated by physicians experienced in the diagnosis and treatment of rheumatoid arthritis.
Croatian: Liječenje moraju započeti liječnici s iskustvom u dijagnosticiranju i liječenju reumatoidnog artritisa.
English: If clinical features of DVT/PE occur, Olumiant treatment should be discontinued and patients should be evaluated promptly, followed by appropriate treatment.
Croatian: Ako se pojave klinički znakovi DVT-a/PE-a, potrebno je obustaviti liječenje lijekom Olumiant i odmah ocijeniti stanje bolesnika te potom uvesti odgovarajuće liječenje.
English: In a long-term extension study, patients from Studies RA-BEAM, RA-BUILD and RA-BEACON who achieved sustained low disease activity or remission (CDAI ≤ 10) after at least 15 months of treatment with Olumiant 4 mg once daily were re-randomized 1:1 in a double-blind manner to continue 4 mg once daily or reduce dose to 2 mg once daily.
Croatian: RA-BEACON koji su postigli održanu nisku aktivnost bolesti ili remisiju (CDAI ≤ 10) nakon najmanje 15 mjeseci liječenja lijekom Olumiant u dozi od 4 mg jedanput na dan bili su ponovno randomizirani u omjeru 1:1, na dvostruko slijep način, za nastavak liječenja dozom od 4 mg jedanput na dan ili za smanjenje doze na 2 mg jedanput na dan.
English: Absolute Neutrophil Count (ANC)
Croatian: Apsolutni broj neutrofila (ABN)
English: Data from clinical studies shows that the incidence rate of urticaria and face oedema is higher in the baricitinib 4 mg arm [urticarial: 0.60; face oedema: 0.89] compared to placebo arm [urticarial: 0.29; face oedema:0.29].
Croatian: Podaci iz kliničkih ispitivanja pokazuju da je stopa incidencije urtikarije i edema lica viša u skupini liječenoj baricitinibom u dozi od 4 mg (urtikarija: 0,60; edem lica: 0,89) nego u onoj koja je primala placebo (urtikarija: 0,29; edem lica: 0,29).
English: However, in clinical studies, treatment was interrupted in response to ANC
Croatian: Međutim, u kliničkim se ispitivanjima liječenje privremeno prekidalo kada je ABN bio
English: - The other ingredients are: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, mannitol, iron oxide red (E172), lecithin (soya) (E322), macrogol, poly (vinyl alcohol), talc and titanium dioxide (E171).
Croatian: manitol, crveni željezov oksid (E172), lecitin (soja) (E322), makrogol, poli(vinilni alkohol), talk i titanijev dioksid (E171).
English: There was no clinically relevant effect on the PK of baricitinib in patients with mild or moderate hepatic impairment.
Croatian: Nije bilo klinički značajnog učinka na farmakokinetiku baricitiniba u bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije.
English: Treatment should be interrupted if Hb < 8 g/dL and may be restarted once Hb return above this value
Croatian: Liječenje treba privremeno prekinuti ako je Hb < 8 g/dl, a može se ponovno započeti kad se Hb vrati iznad te vrijednosti
English: The most common concomitant DMARDs in these subjects were MTX (79% of patients), hydroxychloroquine (19%), leflunomide
Croatian: Najčešći istodobno primjenjivani DMARD-ovi u tih ispitanika bili su metotreksat (79% bolesnika), hidroksiklorokin (19%), leflunomid (11%) i sulfasalazin (9%).
English: - If you have any further questions, ask your doctor, or pharmacist or nurse.
Croatian: - Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili medicinskoj sestri.
English: The PK of baricitinib is linear with respect to time.
Croatian: Farmakokinetika baricitiniba je linearna s obzirom na vrijeme.
English: Herpes zoster, Herpes simplexb Gastroenteritis Urinary tract infections Pneumonia
Croatian: Infekcije i infestacije infekcije gornjih dišnih putovaa herpes zoster herpes simpleksb gastroenteritis infekcije mokraćnih putova pneumonija